Objective: The association between brain injury and elevated serum cardiac troponin (cTn) remains poorly understood. We conducted a systematic review and meta-analysis to evaluate whether elevated cTn increases the risk of mortality in patients with traumatic (TBI) or non-traumatic brain injury (NT-BI). Methods: Cochrane Library, MEDLINE, PubMed, Scopus, Cochrane Central Register of Controlled Trials (CENTRAL), WHO International Clinical Trials Registry Platform, and Google scholar databases, and clinicaltrials.gov were searched for a retrospective, prospective and randomized clinical trials (RCT) or quasi-RCT studies that assessed the effect of elevated cTn (conventional or high sensitive assay) on the outcomes of brain injury patients. The main outcome of interest was mortality. Two authors independently abstracted the data using a data collection form. Results from different studies were pooled for analysis, whenever appropriate. The total number of patients pooled was 2435, of which 916 had elevated cTn and 1519 were in control group. Results: Out of 691 references identified through the search, 8 analytical studies met inclusion criteria. Among both types of brain injuries, an elevated cTn was associated with a higher mortality with an overall pooled odd ratio (OR) of 3.37 (95% CI 2.13-5.36). The pooled OR for mortality was 3.31 (95% CI 1.99-5.53) among patients with TBI and 3.36 (95% CI 1.32-8.6) among patients with NT-BI. Conclusions: Pooled analysis indicates that elevated cTn is significantly associated with a high mortality in patients with TBI and NT-BI. Prospective clinical trials are needed to support these findings and to inform a biomarker risk stratification regardless of the mechanism of injury.
Introduction
In the United States of America, traumatic brain injury (TBI) accounts for up to 30% of all injury-related deaths [1] . It also poses a significant morbidity and economic burden world-wide [2, 3] . While there are significant overall advances in trauma care, the medical management options for head injury remain limited. Based on several retrospective observational studies, TBI is associated with an increased risk of mortality. Some of these studies reported higher rate of mortality in TBI patients who had elevated serum cardiac troponin (cTn) in comparison to those who had normal troponin, even in patients with isolated TBI.
Few studies have evaluated the clinical significance of the release of cTn after trauma [4] [5] [6] [7] . Some of these studies showed that elevated troponin could reflect the degree of severity of overall body injury, regardless of direct cardiac involvement [5, 6] . Furthermore, elevated troponins were reported in acute non-traumatic head injury, including acute stroke (≈27%), and subarachnoid hemorrhage (≈20%) [4, 7] . However, the precise mechanism of elevated cTn is difficult to be determined due to the multitude of prevailing clinical circumstances which may influence troponin release. Moreover, the clinical significance and prognostic value of elevated troponin levels remain poorly explored in TBI patients.
Earlier studies relied mainly on the conventional troponins (TnT or TnI) and did not examine the newer high-sensitive cTn (i.e., HsTnT) which has more sensitivity and shorter time to detect myocardial damage [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . A recent meta-analysis showed that elevated troponins are commonly seen in critically-ill patients even in the absence of coronary artery disease [7, 9, 10, 21] with a prevalence of 45% studies utilized conventional troponin assays [11] , however, this figure reaches 62% with the use of HsTnT [19, 21] . There is very limited data describing the association between troponin and mortality in the context of TBI, as no prospective study has yet examined this association. The use of troponin as a tool in outcome prediction for TBI patients is a relatively novel evidence based concept. In this meta-analysis, we aimed to evaluate whether an elevated cTn increases the risk of mortality in patients with traumatic (TBI) or non-traumatic brain injury (NT-BI).
Objective
The objective of this study is to find out the pooling effect of elevated troponin on the mortality in traumatic or non-traumatic brain injury patients.
Methods
This systematic review was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement. The study was registered at the International prospective register of systematic reviews (PROSPERO n. CRD 42018096594). 
Literature searches

Inclusion/exclusion criteria
The inclusion criteria were (1) original studies, (2) English language, (3) published in the period from 01 January 2000 through 30st April 2018 (4) assessed "Troponin" and "traumatic/non-traumatic brain injury" (5) patients of any age, gender, and ethnicity. Articles other than original studies such as commentaries, letters to the editor, reviews, and case reports were excluded. Literatures that did not include outcomes or comparisons were also excluded.
The consensus on inclusion/exclusion criteria was reached based on the fact that whether the study provides information regarding association between elevated troponin and mortality of patients with brain injury. Therefore, even studies with smaller sample sizes were also included in the initial evaluation.
-Participants: Brain injury patients -Intervention: elevated troponin levels after injury (traumatic or non-traumatic). -Control: normal troponin levels after trauma. -Outcomes: mortality.
Data extraction
The titles of the research articles obtained from the initial database searches were screened and relevant papers were selected. Then the abstracts and full texts were reviewed according to the inclusion criteria for final selection. Studies were reviewed based on the exclusion and inclusion criteria, by two authors (senior cardiologist and bio-statistician) independently (AE and BS). Initially, titles of the studies identified from the search were assessed for inclusion. Titles approved by authors were moved to abstract screening. If both authors rejected a study at this stage, it was excluded from the review. In the third stage, full text articles were screened for eligibility. Only those studies approved by both authors were included in the review. Agreement between the authors on the quality of the articles ranged between 90 and 100%. All the disagreements were resolved by consensus among the authors. Extracted data included authors, the origin of studies, source population, study settings and duration, inclusion/exclusion criteria, data sources and measurement, sample size, and mortality.
Methodological quality
We used "Grading quality of evidence and strength of recommendations" (GRADE criteria) to assess the quality of the included studies and rate the level of evidence. The methodological quality of the selected studies was assessed based on certainty assessment [Study design, Risk of bias, Inconsistency, Indirectness, Imprecision, and Other considerations] by Cochrane Grade pro software. We have evaluated the quality of the proposed outcome i.e. mortality.
Data analysis and synthesis
Odds ratios (OR) were calculated for categorical variables. The decision to select either fixed effect or random effects model depends on results of statistical tests for heterogeneity. Data heterogeneity was assessed using the Cochrane Q homogeneity test with significance set at p b 0.10. If the studies were statistically homogeneous, fixed effect model was selected. A random effects model was used when studies were statistically heterogeneous. The Higgin's I 2 test is the ratio of true heterogeneity to the total variation in observed effects. A rough guide to interpretation of I 2 test is 0 to 25%: might not be important; 25 to 50%: may represent moderate heterogeneity; 50 to 75%: may represent substantial heterogeneity; and N75%: considerable heterogeneity. Publication bias was visually estimated by assessing funnel plots. Pooled estimates of mortality were calculated using a Microsoft Excel add-in, MetaXL v. 5.3 (EpiGear International Pty Ltd., Sunrise Beach, Queensland, Australia). GRADEpro GDT was used for studies grading.
Results
The search produced a total of 691 articles; 640 articles were either non-relevant to the topic, duplicates or review articles which were excluded initially. The relevant titles and/or abstracts and full text of the 51 articles underwent detailed evaluation; of which 41 articles were further eliminated which were mainly based on protocol development and narrative reviews and the remaining 10 articles studies [6, 7, 12, [14] [15] [16] [17] [18] [19] [20] were reviewed further. Among them, two studies [6, 20] were excluded as per the criteria for meta-analysis and both did not have sufficient information regarding categorizing the troponin status or did not assess the outcome (mortality). Finally, eight original studies met all the review criteria and were considered for the final meta-analysis ( Fig. 1 , Table 1 ) [7, 12, [14] [15] [16] [17] [18] [19] . Median study duration was 4.4 years with an IQR 3-6.5 years. The total number of patients pooled was 2435, of which 916 were in elevated troponin group and 1519 in control group. Overall average age was 49.6 years. Table 2 shows the details of the quality assessment based on GRADE criteria of the seven selected observational studies (all retrospective). All studies were of moderate quality. Tables 2 & 3 demonstrate the quality assessment of the included seven studies which shows the moderate level of evidence based on GRADE criteria.
Outcome measures
Effect of elevated troponin level on mortality in overall brain injury [TBI and NT-BI]
Eight brain injury studies compared the mortality in the elevated troponin group with a control group. Total of 826 patients died after all types of brain injury [431 in elevated troponin group and 395 in control group] with a post hoc statistical power of 100% (Fig. 2) . The pooled result manifested a statistically significant increase in mortality in the elevated troponin group compared to the control group (OR 3.37 (95% CI 2.13-5.36)). A further subgroup analysis with only conventional troponin (cTnI) showed an odds ratio (OR 3.09 (95% CI 1.90-5.03)) for mortality in the elevated troponin group compared to the control group.
Effect of elevated troponin level on mortality in TBI
Three traumatic brain injury studies [total sample size = 1540] compared the mortality in the elevated troponin group with a control group. Total of 586 patients died after TBI [310 in elevated troponin group and 276 in control group] with a post hoc statistical power of 100% (Fig. 3) .
The pooled result manifested a statistically significant increase in mortality in the elevated troponin group compared to the control group (OR 3.31 (95% CI 1.99-5.53)).
Effect of elevated troponin level on mortality in NT-BI
Four NT-BI studies [total sample size = 895] compared the mortality in the elevated troponin group with a control group. Total of 240 patients died after NT-BI [121 in elevated troponin group and 119 in control group] with a post hoc statistical power of 100% (Fig. 4) . The pooled result manifested a statistically significant increase in mortality in the elevated troponin group compared to the control group (OR 3.36 (95% CI 1.32-8.6)).
Full text original articles reviewed (n = 10)
studies of Traumatic brain injury (Sample size =1540):
Salim et al. [12] , Cai et al. [18] , El-Menyar et al. [19] , Hasanin et al [7] 4 studies of Non-traumatic brain injury (Sample size =895):
Hays & Diringer. [14] , Ramappa et al. [15] Sandhu et al. [16] , Gupte et al. [17] [7] Severe TBI 1 year prospective observational study. Cohort of 50 patients with severe TBI. In hospital mortality was (32) 64%. Elevated troponin was in 27 patients and rest was control.
To report the incidence of cardiac injury in patients with TBI and its impact on patient outcome.
TnI
In hospital mortality was (32) 64%. Elevated troponin was in 27 patients and rest was control. There were 22 mortalities in elevated troponin group (27) and 10 mortalities in normal (23 No. The study population was SAH, intervention was elevated troponin level vs normal, and outcome assessment was consistent in terms of mortality.
No. The study population was severe TBI, Intervention was elevated troponin level vs normal, and outcome assessment was consistent in terms of mortality.
Yes. This study has wide confidence interval. The study population was ICH and SAH patients, intervention was elevated troponin level vs normal, and outcome assessment was consistent in terms of mortality.
No. The study population was SAH patients, intervention was elevated troponin level vs normal, and outcome assessment was consistent in terms of mortality.
No. The study population was severe TBI, intervention was elevated troponin level vs normal, and outcome assessment was consistent in terms of mortality.
No. The study population was intubated traumatic brain injury patients, intervention was elevated troponin level vs normal, and outcome assessment was consistent in terms of mortality.
Indirectness
There is no indirectness as all adult [mean age 52] ICH patients were included, intervention was cTnI ≥ 0.10 ng/mL, and comparator group was similar with cTnI b 0.10 ng/mL, outcome measure was appropriate to assess the effect of intervention.
There is no indirectness as all adult [mean age 59] SAH patients were included, intervention was cTnI ≥ 2.0 ng/mL, and comparator group was similar, with cTnI b 2.0 ng/mL outcome measure was appropriate to assess the effect of intervention.
There is no indirectness as all adult [mean age 43.9] severe TBI patients were included, intervention was cTnI N 0.30, and comparator group was similar with cTnI ≤ 0.30 ng/mL, outcome measure was appropriate to assess the effect of intervention.
There is no indirectness as all adult [mean age 67] ICH and SAH patients were included, intervention was cTnI N 0.4 ng/mL, and comparator group was similar with cTnI ≤ 0.14 ng/mL, outcome measure was appropriate to assess the effect of intervention.
There is no indirectness as all adult [mean age 57.3] SAH patients were included, intervention was cTI N 0.5 ng/mL, and comparator group was similar, with cTnI ≤ 0.5 ng/mL outcome measure was appropriate to assess the effect of intervention. a This study has low or unclear risk of bias. Plausible bias unlikely to seriously alter the results. This study has no serious risk of bias, which does not downgrade the quality. 
Heterogeneity among included studies
The results for the test of heterogeneity for the meta-analysis of effect of elevated troponin level on mortality were displayed towards the bottom of the forest plot in the line: for all brain injury studies Q [χ2] = 33.16, p = 0.001, I 2 = 79%, tau 2 = 0.326 (Fig. 2) , for TBI Q
[χ2] = 10.01, p = 0.02, I 2 = 70%, tau 2 = 0.174 (Fig. 3) , for NT-BI Q
[χ2] = 23.12, p = 0.001, I 2 = 87%, tau 2 = 0.788 (Fig. 4) . However, I
2 was N75%, a random effect model was considered. Tau 2 reflected the amount of true heterogeneity among the studies, which was less in the TBI group, compared to other two groups (NT-BI and overall brain injuries).
Publication bias and funnel plots
For all of the above analyses, sensitivity analysis yielded consistent results. Based on a visual inspection of the funnel plot, there has been no evidence of publication bias for the included studies (Fig. 5) .
Discussion
The present meta-analysis highlights the utility of serum cardiac troponins testing post-brain injury regardless of the mechanism of injury. Although, there is no published randomized clinical trial yet, at least 10 published studies have addressed the association of elevated serum cardiac troponins and risk of mortality in patients with brain injury [6, 7, 12, [14] [15] [16] [17] [18] [19] [20] . We identified eight, moderate-quality observational studies that described this association and met the inclusion criteria for metaanalysis [7, 12, [14] [15] [16] [17] [18] [19] . Fig. 1 summarizes each study population based on the troponin status and outcome. The mortality rates were greater in those who had positive troponin test regardless of the type of brain injury (traumatic or non-traumatic) in comparison to those who had normal troponin test. Also, the type of troponin assay did not change such relationship between the test positivity and mortality post-brain injury.
Seven studies using cTnI were conducted in the United States of America (n = 6) and Egypt (n = 1) [7, 12, [14] [15] [16] [17] [18] , while one study from Qatar utilized HsTnT assay [19] . Four retrospective studies [7, [15] [16] [17] were under powered and having wide confidence interval, whereas the other four retrospective studies were appropriately powered to measure the study outcomes.
There is one meta-analysis assessed cTn use in non-cardiac patients from 25 studies [21] . These studies included patients who were admitted to an intensive care unit (n = 10 studies), patients with pulmonary embolism (n = 7 studies), sepsis (n = 5 studies), chronic obstructive lung disease (n = 3 studies), diabetic ketoacidosis (n = 1 study), and hypertensive emergency (n = 1 study). Among these studies, the cardiac troponins used included cTnI (n = 17), cTnT (n = 8) and HsTnT (n = 2). Based on the inclusion criteria and search, the use of the conventional serum Troponin T in TBI studies has not been reported yet [22] . Elevated troponin and 30-day in-hospital mortality showed a pooled OR of 3.88 (95% CI 2.90-5.19). The duration of the included studies follow-up ranged from 28 days to 4 years, until discharge or up to inhospital mortality. In addition, there was an increased risk of long-term mortality at 6 months while pooling six studies (OR 4.21, 95% CI 1.84-9.64). All these studies were graded a moderate quality evidence for both long-and short-term mortality but this meta-analysis did not include any brain injury studies [21] .
In patients with TBI, Salim et al. [12] found that elevated cTnI is an independent predictor of in-hospital mortality (OR 1.94, 95% CI (1.26-3.00)). Further in 2016, Cai et al. reported that elevated cTnI level was an independent predictor of in-hospital mortality (OR 2.85, 95% CI (1.97-4.12)), showing a dose-response trend [18] . Hasanin et al. [7] also reported that elevated cTnI level increased the inhospital mortality (OR 5.72, 95% CI (1.6, 20.45)). In 2018, El-Menyar et al. found that positive HsTnT was associated with in-hospital mortality among TBI patients (OR 5.95, 95% CI (3.29-10.76)). Our metaanalysis showed among TBI patients, the effect of elevated troponin on mortality had a pooled odds ratio of 3.31 (95% CI 1.99-5.53) among TBI patients and 3.36 (95% CI 1.32-8.6) among NT-BI patients.
There are several factors that could explain the release of troponin in patients with TBI apart from the direct cardiac contusion. These factors include stress-induced hyperadrenergic status that may cause microthrombosis, coronary spasm, cardiomyopathy or arrhythmias [19, 22, 23] . Similarly, NT-BI such as acute stroke has been found to increase sympathetic tone and the risk of arrhythmias and myocardial damage [22] . The sympathetic activity measured by plasma norepinephrine levels were found to be higher in the stroke patients compared with the control group [22] . In one study evaluated TnI release as a prognostic marker in patients with subarachnoid hemorrhage, found that peak TnI levels were associated with a significantly increased risk of LV dysfunction [24] . Also, patients with subarachnoid hemorrhage were found to have a threefold greater in their plasma norepinephrine levels [25] .
This meta-analysis could be of great clinical interest to improve survival and functional outcomes of TBI patients, as there are no guidelines or consensus for management of TBI patients based on the cardiac marker (i.e. troponin test status) yet. We suggest the use of high sensitive troponin assay to detect myocardial injury at early stage (within the first 3 h post-brain injury); however its cost-effectiveness in comparison to the conventional assay needs further evaluation. Serum cardiac Troponin test may rapidly identify patients at high risk of death for whom beta blockers could have a substantial clinical benefit (if no contraindication) by counteracting the effect of brain injury-induced catecholamine surge [12, 19, 22, 23] . The present meta-analysis could raise the debate for a potential therapeutic use and benefit of early beta blockers administration in patients with brain injury regardless of the mechanism of injury and based on the initial troponin results.
A recent meta-analysis [26] included 9 studies (2005 TBI patients with beta blocker use and 6240 without beta blockers), showed that beta blockers use post-TBI was associated with a significant reduction of hospital death (pooled OR 0.39, 95% CI: 0.27-0.56). The authors conditionally recommended the hospital beta blockers use in adults with acute TBI with no contraindications (i.e., heart rate b 50 with symptoms or SBP b 90 mm Hg). Studies in the meta-analysis [26] showed a consistent effect and did not report a significant cardiovascular deterioration from the beta blockers use; however, this recommendation was based on a synthesis of low quality studies that necessitate further prospective randomized clinical trials with enough power to initiate a cascade for practical changes.
Limitations
The searches for this review were in most of the citation databases and reference lists from the included studies and we have accessed the paid articles as well. We also contacted the authors to fix errors in one published paper [7] . Our study included the published studies as we could not find out the gray literature that was not published and so we admit the potential publication bias. Inclusion of only eight studies in this meta-analysis could be one of the limitations, however, we have done a post hoc power calculation for mortality comparison, there were 395 mortality out of 1519 in control group (normal troponin) and 431 out of 916 in intervention group (elevated troponin) which showed a power of 100% at 5% significance level. The timing to check troponin post-brain injury is also an important cofounder. The associated direct cardiac injury was not given in most of the studies included in this meta-analysis. Moreover, outcomes in these studies were not adjusted for the thoracic injuries except for one study [19] .
In conclusion, elevated troponin is associated with higher mortality in patients with traumatic and non-traumatic brain injury. Furthermore, high-quality prospective clinical trials are needed to support the implication of troponin as a prognostic marker in brain injury patients. 
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